Global healthcare company Abbott (NYSE:ABT) announced on Monday the release of Libre Assist, a new feature within the Libre app.
Libre Assist is designed to help people living with diabetes in the US better understand how the foods they eat affect their glucose levels. Unlike traditional food logging apps that only give feedback after a meal is logged, Libre Assist is designed to help people make informed mealtime decisions before they eat.
Using generative artificial intelligence (AI), the feature illustrates the potential glucose impact of a food choice with a color-coded rating system -- green for minor, yellow for moderate, and orange for major.
Abbott is launching the new technology during CES 2026 in Las Vegas.
FDA grants priority review for Sanofi's Tzield in young children with stage 2 type 1 diabetes
Samsung Bioepis begins direct commercialisation of BYOOVIZ in Europe
Diamyd Medical agrees accelerated efficacy readout in ongoing Phase 3 type 1 diabetes trial
Clywedog Therapeutics activates all clinical centres and patient dosing in balomenib Phase 1b study
Qlife's Egoo Health platform selected for major AI-driven diabetes and MASLD project in China
ALR Technologies announces GluCurve Pet CGM relaunch in Canada
Gan & Lee Pharmaceuticals launches third phase 3 trial of once-monthly bofanglutide
Novo Nordisk reports strong phase 2 results for amycretin in type 2 diabetes
Innovent Biologics reports primary and all key secondary endpoints met in mazdutide Phase 3 trial
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin